Chemotherapy in all stage gastric MALT lymphomas: results from the literature34 36 102 122 123 125–131
| First author and year | No. of patients | Treatments | Response | Outcome | Comments |
| Hammel, 1995 | 24 | Continuous alkylating agents cyclophosphamide or chlorambucil | 75% CR | Median FU 14 months, 28% relapses | All stages I–IV. Non-treated. ‘Prominent’ gastric involvement |
| Levy, 2005 | 21 | Continuous alkylating agents 12 cases t(11;18)+ 9 cases t(11;18)− | (+) 42% CR (−) 89% CR | (+) 8% persistent CR at 7 years (−) 89% persistent CR at 7 years | All stages I–IV. Non-treated. Alkylating agents not active in t(11;18)+ |
| Aviles, 2005 | 83 | Alternating CHOP21/CVP | Median FU 7.5 years, 87% EFS, 87% OS at 10 years | Early stages IE–IIE. Non-treated, no H pylori eradication | |
| Wohrer, 2005 | 5* | Mitoxantrone/chlorambucil and prednisone (MCP) | 4 (80%) CR 1 (20%) PR | Stages I–II. Chemotherapy-naive. Previous H pylori eradication | |
| Jager, 2002/2006 | 19* | 2CdA | 100% CR | FU 80 months 3/19 (15%) relapses 78.5% DFS | All stages I–IV. Chemotherapy-naive. Active in t(11;18)+. Risk of myelodysplasia? |
| Raderer, 2005 | 4* | Oxaliplatin | 2 (50%) CR 1 (25%) PR | No relapses at time of publication | All stages I–IV. Treated and non-treated. Active in t(11;18)+ |
| Raderer, 2003 | 7 gastric* | Rituximab | 3 (33%) CR 2(22%) PR† | FU 8–14 months. No relapses after CR | All stages I–IV. Treated and non-treated. Still CD20 cells in LEL(+) |
| Conconi, 2003 | 14* | Rituximab | 9 (64%) OR 4 (29%) CR5 (35%) PR | Median FU 14.2 months | All stages I–IV. Treated and non-treated. Better in non-treated |
| Martinelli, 2005 | 26 | Rituximab | 20 (77%) OR 12 (46%) CR 8 (31%) PR | Median FU 33 months, 2/20 relapses | All stages I–IV. Treated and non-treated. Active in t(11;18)+ |
| Wohrer, 2007 | 7* | R-CHOP/R-CNOPP | 7 (100%) OR 5 (71%) CR 2 (29%) PR | FU 10–23 months. No relapses after CR. PR stable | All stages I–IV. Treated and non-treated. Active in t(11;18)+. Haematological toxicity |
| Salar, 2009 | 10* | Rituximab+fludarabin | 100% CR 91% CR after 3cycles | FU 24 months. No relapses after CR. 100% PFS at 24 months | All stages I–IV. Chemotherapy-naive. Active in t(11;18)+ |
| Levy, 2010 | 13 | Rituximab+clorambucil | 100% CR | Median FU 24 months. No relapse, 2 adenocarcinoma operated on | All stages I–IV all t(11;18)+. Treated and non-treated |
↵* Series include lymphomas from other MALT sites. Data in the table refer only to gastric MALT lymphomas.
↵† Percentage results refer to 7 gastric and 2 non-gastric lymphomas.
Non-treated, no previous treatment, except H pylori eradication; chemotherapy-naive, no previous treatment with chemotherapy. Other treatments eventually used.
2CdA, cladribine; CR, complete response; DFS, disease-free survival; EFS, event-free survival; FU, follow-up; (+) LEL, lymphoepithelial lesions in gastric mucosa; MALT, mucosa-associated lymphoid tissue; OR, overall response; OS, overall survival; PR, partial response; R-CHOP/R-CNOPP, rituximab plus cyclophosphamide, vincristine, prednisone with either doxorubicin or mitoxantrone.